Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Date of authorisation: 28/06/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,avibactam, Date of authorisation: 22/04/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Date of authorisation: 17/07/2025, Status: Authorised

EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 2: Format for the electronic submission of veterinary medicinal product information

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 14, Status: Authorised

Mpox

Orphan designation: idebenone Treatment of Leber's hereditary optic neuropathy, 16/02/2007 Expired

Orphan designation: Panobinostat Treatment of multiple myeloma, 08/11/2012 Expired

LinkedIn Live: Smarter trials, stronger Europe. New targets for clinical research., European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 24 September 2025, 14:00 (CEST) to 24 September 2025, 15:00 (CEST)

Human Medicines